CD177 and biliary atresia: The use of N-acetylcysteine can reduce the percentage of CD177+ neutrophils and NETosis, indicating that it has potential therapeutic value for patients with biliary atresia (73), but the exact function of CD177+ neutrophils remains elusive in liver injury.